Epitalon
/ Synthetic tetrapeptide Ala-Glu-Asp-GlyALIAS · Epithalon · Epithalamin (parent preparation)
Terms in this page you can click for a plain-English popup: , , , , , , , .
Among the weakest independent evidence bases of any peptide covered on Open Assay. Telomerase-elongation claims from the Khavinson lab have not been independently replicated by Western labs. Longevity claims rest on single-institute Russian cohort data.
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. The parent preparation, Epithalamin, is a bovine pineal extract. Proposed mechanisms include upregulation of telomerase activity in somatic cells, modulation of pineal melatonin rhythms, and epigenetic modulation of gene expression. The telomerase-activation claim rests heavily on one research group’s data.
Effectively zero rigorous Western RCTs. Russian longitudinal data (Korkushko, Khavinson) exist but are predominantly open-label, single-institute, and not independently replicated. No ClinicalTrials.gov entries from Western centers.
Russian literature reports no significant adverse events. Independent Western safety data do not exist.
Regulatory status
- FDA status:
- Not FDA-approved
Epitalon has among the weakest independent evidence bases of any peptide on Open Assay. Telomerase-elongation claims are striking but have not been independently replicated by Western labs. Longevity claims rest on non-randomized Russian cohort data from a single institute across multiple decades.